Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics

Zentalis Pharmaceuticals Inc. (ZNTL): $23.60

0.10 (+0.43%)

POWR Rating

Component Grades













Add ZNTL to Watchlist
Sign Up

Industry: Biotech



in industry

ZNTL Stock Price Chart Interactive Chart >

Price chart for ZNTL

ZNTL Price/Volume Stats

Current price $23.60 52-week high $59.65
Prev. close $23.50 52-week low $17.33
Day low $23.44 Volume 666,528
Day high $24.52 Avg. volume 600,066
50-day MA $21.05 Dividend yield N/A
200-day MA $24.17 Market Cap 1.35B

Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

ZNTL Latest News Stream

Event/Time News Detail
Loading, please wait...

ZNTL Latest Social Stream

Loading social stream, please wait...

View Full ZNTL Social Stream

Latest ZNTL News From Around the Web

Below are the latest news stories about ZENTALIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZNTL as an investment opportunity.

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | January 17, 2023

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on January 3, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 30,625 shares of the Company’s common stoc

Yahoo | January 3, 2023

Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 170.4% in Zentalis Pharmaceuticals, Inc. (ZNTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 8, 2022

These 4 “Strong Buy” Stocks are on Analysts’ Radars

German economist Karl Otto Pohl once famously compared inflation with toothpaste — "Once it's out, you can hardly get it back in again," he had said. However, October's inflation reading gave us some hope, having cooled to 7.7% year-over-year. Nonetheless, this is far from the Federal Reserve's target inflation rate of 2%-3%, and the economy still has a long way to go. In such an environment, stocks that Wall Street analysts are rooting for are worth keeping an eye on. Here are four "Strong Buy" stocks to consider—Duolingo (NASDAQ:DUOL), Jazz Pharmaceuticals (NASDAQ:JAZZ), Trade Desk (NASDAQ:TTD), and Zentalis Pharmaceuticals (NASDAQ:ZNTL). Duolingo (DUOL) Mobile language learning platform provider Duolingo recently posted revenue and earnings beats.

Chandrima Sanyal on TipRanks | November 14, 2022

Analysts Offer Insights on Healthcare Companies: Sol-Gel Technologies (SLGL), Zentalis Pharmaceuticals (ZNTL) and Oncology Institute, Inc. (TOI)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sol-Gel Technologies (SLGL – Research Report), Zentalis Pharmaceuticals (ZNTL – Research Report) and Oncology Institute, Inc. (TOI – Research Report) with bullish sentiments. Sol-Gel Technologies (SLGL) Raymond James analyst Elliot Wilbur maintained a Buy rating on Sol-Gel Technologies today and set a price target of $13.00. The company's shares closed last Friday at $4.74, close to its 52-week low of $3.94. According to TipRanks.

Christine Brown on TipRanks | November 11, 2022

Read More 'ZNTL' Stories Here

ZNTL Price Returns

1-mo 17.18%
3-mo -3.67%
6-mo -23.13%
1-year -58.65%
3-year N/A
5-year N/A
YTD 17.18%
2022 -76.04%
2021 61.84%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6497 seconds.